Study of Genes and the Environment in Patients With Colorectal Cancer in the East Anglia Region of the United Kingdom
|ClinicalTrials.gov Identifier: NCT00757965|
Recruitment Status : Unknown
Verified September 2008 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : September 23, 2008
Last Update Posted : August 26, 2013
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This study is looking at genetic susceptibility for cancer and interactions between genes and the environment in patients with colorectal cancer.
|Condition or disease||Intervention/treatment|
|Colorectal Cancer||Genetic: polymorphism analysis Other: laboratory biomarker analysis Other: questionnaire administration|
- To obtain epidemiological information and biological material on a population based series of colorectal cancer cases.
- To define the proportion of colorectal cancer incidence attributable to mutations in known predisposing genes such as MLH1 and MSH2.
- To establish whether mutations at other loci may predispose to colorectal cancer, by comparing the frequency of alteration candidate genes in colorectal cancer patients with the corresponding frequency in cancer-free controls identified through the European Prospective Investigation of Cancer (EPIC) study.
OUTLINE: This is a multicenter study.
Patients complete an epidemiological questionnaire. The questionnaire also requests identifying information about the patient's first-degree relatives.
Blood samples are collected from patients. DNA is extracted from these blood samples, from samples collected from cancer-free control participants in MREC-SEARCH-CONTROL, and from additional controls through the European Prospective Investigation of Cancer (EPIC) study (a population-based study of diet and health based in Norfolk, East Anglia). DNA samples are analyzed for polymorphisms of low penetrance cancer susceptibility genes.
In addition to the colorectal cancer patients recruited for this study, patients with breast, ovarian, prostate, colorectal, bladder, kidney, pancreatic, brain, and esophageal cancer, malignant melanoma, and lymphoma cancer are recruited for the following related clinical trials: MREC-SEARCH-BREAST, MREC-SEARCH-OVARIAN, MREC-SEARCH-PROSTATE, MREC-SEARCH-ENDOMETRIAL, and MREC-SEARCH-CANCER.
|Study Type :||Observational|
|Estimated Enrollment :||2000 participants|
|Official Title:||A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Colorectal Cancer in East Anglia|
|Study Start Date :||February 2008|
- Acquisition of epidemiological information and biological material
- Proportion of colorectal cancer incidence attributable to mutations in known predisposing genes (e.g., MLH1 and MSH2)
- Exploration of mutations at other loci that may predispose to endometrial cancer
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00757965
|University of Cambridge Cancer Research UK||Recruiting|
|Cambridge, England, United Kingdom, CB1 8RN|
|Contact: Contact Person 44-122-374-0166 firstname.lastname@example.org|
|Study Chair:||Paul Pharoah, MD||Cancer Research UK|